Sarcopenia in pancreatic cancer: Effect on patient outcomes
Authors:
Open Access
- 15 December 2022
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 14 (12) , 2302-2312
Abstract
Sarcopenia in pancreatic cancer: Effect on patient outcomesKeywords
This publication has 44 references indexed in Scilit:
- Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancerOncology Reports, 2015
- Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess SarcopeniaJournal of Gastrointestinal Surgery, 2015
- Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic CancerAnnals of Surgical Oncology, 2014
- Sarcopenia in Asia: Consensus Report of the Asian Working Group for SarcopeniaJournal of the American Medical Directors Association, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass IndexJournal of Clinical Oncology, 2013
- Impact of Sarcopenia on Outcomes Following Resection of Pancreatic AdenocarcinomaJournal of Gastrointestinal Surgery, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008